PWM
BBIO icon

Parkworth Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Parkworth Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$216 Buy
5
+2
+67% +$73 ﹤0.01% 927
2025
Q1 		$104 Hold
3
– – ﹤0.01% 924
2024
Q4 		$82 Buy
+3
New +$78 ﹤0.01% 1041

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Parkworth Wealth Management's BBIO Position: Q2 2025 in Review

Parkworth Wealth Management increased its BridgeBio Pharma (BBIO) stake by 67% in Q2 2025, buying an estimated $73 and bringing the position to 5 shares worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Parkworth Wealth Management first reported a position in BBIO in Q4 2024 and has held it in 3 quarters since. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • Parkworth Wealth Management held 5 shares of BridgeBio Pharma worth $216 as of Q2 2025.
  • Parkworth Wealth Management bought 2 BridgeBio Pharma shares in Q2 2025, an estimated $73.
  • BridgeBio Pharma made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #927 holding.
  • Parkworth Wealth Management first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 3 quarters since.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.